BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in gain of 15 or more letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
All cause mortality · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics leads to lower all cause mortality compared with placebo or no intervention (high certainty).
1 finding from 1 review
Febrile patients and episodes · patients with afebrile neutropenia induced by chemotherapy
Summary of findings: antibiotics probably leads to lower febrile patients and episodes compared with placebo or no intervention (moderate certainty).
1 finding from 1 review
Median (mean) time to use of rescue medication · health problem or population
1 finding from 1 review
Number of participants reporting an adverse event · health problem or population
It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants reporting or experiencing any adverse event compared with active comparator (acetaminophen) (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · health problem or population
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
At least 50% reduction in pain · health problem or population
It is very uncertain whether summary of Findings Table ‐ Ibuprofen 300 mg changes number of participants with at least 50% pain relief at 4 hours compared with active comparator (acetaminophen) (very low certainty).
2 findings from 1 review
Number of participants using rescue medication over 4 to 6 hours postinterventions · health problem or population
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dyspnoea ‐ CRQ dyspnoea Scale 1 to 7. Higher is better and 0.5 units is a clinically important difference · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Adverse eventsd · patients with chronic obstructive pulmonary disease
1 finding from 1 review
General health‐related quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life (mental) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease
1 finding from 1 review
QoL · adults (aged 16 years and over) with CF
1 finding from 1 review
FEV1 % predicted · adults (aged 16 years and over) with CF
1 finding from 1 review
Pulmonary exacerbations · adults (aged 16 years and over) with CF
1 finding from 1 review
Adherence to inhaled therapies cMPR · adults (aged 16 years and over) with CF
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · adults (aged 16 years and over) with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found